Most Read Articles
Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Tristan Manalac, 11 Jan 2019
Less than 15 percent of Singaporean adolescents get the recommended 8–10 hours of sleep on a school night, reports a recent study, noting that such short sleep duration is linked to symptoms of depression, overweight or obesity, and poorer self-rated health.
04 Jan 2019
Obstructive sleep apnoea may increase the risk of male-pattern baldness in men with a family history of hair loss, and this association appears to be mediated by low serum transferrin saturation levels related to hypoxia, a study suggests.
6 days ago
Airway type 2 inflammation remains persistent in many asthmatics on inhaled corticosteroids, a new study has shown. These patients tend to be older and have a more severe disease.

IBI-10090 dexamethasone drug-delivery suspension safe, effective for postoperative inflammation

03 Jun 2018

An anterior chamber intracameral dexamethasone drug-delivery suspension (IBI-10090) at concentrations of 342 and 517 μg is safe and effective in treating postoperative inflammation in patients undergoing cataract surgery, according to a study. In addition, IBI-10090 may replace corticosteroid drop installation in these patients.

A total of 394 patients undergoing unilateral cataract surgery by phacoemulsification were randomized to receive 5-μl injections of placebo or 5-μl injections of 342 or 517 μg IBI-10090 dexamethasone drug delivery suspension injected into the anterior chamber. All patients were followed for 90 days after surgery.

Anterior chamber cell (ACC) clearing (ACC score of 0) in the study eye at postoperative day (POD) 8 was the primary outcome. Secondary outcomes were anterior chamber flare and ACC plus flare clearing in the study eye. The investigators also assessed ocular and nonocular adverse events.

More eyes in the 342- and 517-μg IBI-10090 treatment groups (63.1 percent and 66.0 percent, respectively) vs the placebo group (25.0 percent) achieved ACC clearing at POD 8 (p<0.001). Likewise, more eyes in the 342- and 517-μg treatment groups (92.4 percent and 89.1 percent, respectively) vs the placebo group (63.8 percent) achieved anterior chamber flare clearing at POD 8 (p<0.001).

Moreover, anterior chamber cell plus flare clearing at POD 8 was achieved in 63.1 percent and 67.3 percent of eyes receiving 342- and 517-μg IBI-10090, respectively, and in 33.8 percent of eyes receiving placebo (p<0.001).

Adverse events were comparable among the three groups, and there were no reports of serious ocular adverse events up to POD 90.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Tristan Manalac, 11 Jan 2019
Less than 15 percent of Singaporean adolescents get the recommended 8–10 hours of sleep on a school night, reports a recent study, noting that such short sleep duration is linked to symptoms of depression, overweight or obesity, and poorer self-rated health.
04 Jan 2019
Obstructive sleep apnoea may increase the risk of male-pattern baldness in men with a family history of hair loss, and this association appears to be mediated by low serum transferrin saturation levels related to hypoxia, a study suggests.
6 days ago
Airway type 2 inflammation remains persistent in many asthmatics on inhaled corticosteroids, a new study has shown. These patients tend to be older and have a more severe disease.